Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01509638 · ClinicalTrials.gov registry record · Phase 4
A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501
A Phase 4 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 47
- Enrollment target
NCT01509638 is a Phase 4 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 47 participants.
The verdict
NCT01509638, a Phase 4 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 47 participants
- Enrollment target
Study Summary
This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.
Interventions
- DRUG Group 1 Standard of Care
- DRUG Group 2 EXPAREL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01509638
The ClinicalTrials.gov registry entry for NCT01509638 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Group 1 Standard of Care is the first listed.
NCT01509638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01509638 about?
NCT01509638 is a clinical study titled "A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501". This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.
What is the current status of trial NCT01509638?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 47 participants. The study started on 2012-03. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01509638?
The interventions under investigation include: Group 1 Standard of Care (DRUG), Group 2 EXPAREL (DRUG).
Who is sponsoring clinical trial NCT01509638?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.